Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...
CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...
Please provide your email address to receive an email when new articles are posted on . In patients having TAVR, cerebral embolic protection reduced risk for periprocedural stroke in patients from the ...
Stroke remains a problem after TAVR and continues to feed discussions around how extensively cerebral embolic protection devices and other strategies should be used. In a session during TVT Connect, ...
CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
A US Food and Drug Administration (FDA) advisory panel struggled to muster support for marketing clearance of the TriGuard 3 (Keystone Heart) device for use during transcatheter aortic valve ...
TipRanks on MSN
MicroPort NeuroTech steps up competition in brain vascular devices with new embolic agent trial
MicroPort NeuroTech Limited ($HK:2172) announced an update on their ongoing clinical study. Study Overview The clinical study “a Prospective, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback